Almac to Partner with Lilly UK on Lung Cancer Dx | GenomeWeb

NEW YORK (GenomeWeb News) – Almac Diagnostics said today that it will collaborate with Lilly UK to develop a companion diagnostic for a combination lung cancer therapy.

The companies will evaluate a predictive marker for a drug combination used in treating non-squamous, non-small cell lung cancer patients. Specifically, they will study Thymidylate Synthase as a marker for response to the Eli Lilly drug pemetrexid (Alimta) in combination with cisplatin.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.